

Inflammatory Bowel Disease Therapeutics: Market Research Report

<https://marketpublishers.com/r/I67534ADEA7EN.html>

Date: April 2010

Pages: 611

Price: US\$ 3,950.00 (Single User License)

ID: I67534ADEA7EN

Abstracts

This report analyzes the Global market for Inflammatory Bowel Disease Therapeutics in US\$ Million.

Annual estimates and forecasts are provided for the period 2006 through 2015.

The report profiles 69 companies including Abbott Laboratories, Biogen Idec, Inc., Cosmo Pharmaceuticals SpA, ChemoCentryx, Inc., Dr. Falk Pharma GmbH, Eisai Co., Ltd., Elan Corporation, plc, Ferring Pharmaceuticals A/S, GlaxoSmithKline plc, Johnson & Johnson, Centocor Ortho Biotech, Inc, Kyorin Pharmaceutical Co., Ltd., Merck Serono, Millennium Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma Corporation, Novartis AG, Otsuka Pharmaceutical Co.Ltd., Prometheus Laboratories, Inc., Shire plc, UCB SA, and Wyeth.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1.INDUSTRY OVERVIEW

Introduction
Biological Drugs Lead the IBD Therapeutics Bandwagon
Leading Biological Drugs Approved for Treatment of Crohn's Disease
Year of Approval for Leading Drugs in Crohn's Disease Treatment
Impact of the Economic Recession on the Pharmaceutical Industry
Recession Brings Drug Development Efforts Under Siege
Biotech Bankruptcies Rife in the Current Economic Downturn
Current and Future Analysis

Table 1. World Recent Past, Current & Future Analysis for Inflammatory Bowel Disease Therapeutics by Disease Type – Crohn's Disease and Ulcerative Colitis Markets Independently Analyzed with Annual Sales in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 2. World 9-Year Perspective for Inflammatory Bowel Disease Therapeutics by Disease Type – Percentage Breakdown of Dollar Sales for Crohn's Disease and Ulcerative Colitis Markets for the Years 2006, 2009 & 2015

Regional Market Overview

United States

Lialda's Share Gaining Momentum in Ulcerative Colitis Drugs Market
Key Ulcerative Colitis Drugs in the US (2006)

Table 3. US Ulcerative Colitis Drugs Market (2007 & 2008): Percentage Breakdown of Prescriptions Dispensed Ranked by Leading Drugs for Asacol, Pentasa, Lialda, Canasa, Sulphasalazine, Colazal, Other Drugs and Generics (includes corresponding Graph/Chart)

Canada

Key Challenges Lie ahead

Productivity Loss to the Nation

Australia

Japan

Europe

Increasing Awareness to Drive Market Growth

United Kingdom

2.IBD - AN OVERVIEW

Prevalence and Incidence

Women More Susceptible to IBD

Etiology of Inflammatory Bowel Disease

Genetic Predisposition

Environmental Factors

IBD – A Health and Social Burden

Inflammatory Bowel Disease Types

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Clinical Manifestations

Signs and Symptoms

Diagnosis

Pathogenesis

Outcomes

Treatment Strategies

Step I (Aminosalicylates)

5-AMINOSALICYLIC ACID (5-ASA) DERIVATIVES AND AVAILABLE BRANDS IN THE US MARKET

Step II (Antibiotics)

Step III (Corticosteroids)

Available Corticosteroidal Drugs As per Mode of Administration

Step IV (Immuno-modifying Agents)

Overview of Select Biological Drugs

Infliximab (Remicade)

Adalimumab (Humira)

Certolizumab pegol (Cimzia)

Natalizumab (Tysabri)

Step V (Experimental Medication)

Experimental Medication Drugs for IBD with Dosage Settings

Ileal Pouch recommended in Conditions of Ulcerative Colitis

Comparing Crohn's Disease and Ulcerative Colitis

Comparison of Characteristics of Ulcerative Colitis and Crohn's Disease

3.PRODUCT INNOVATIONS/LAUNCHES

Procter & Gamble Pharmaceuticals Introduces Asacol HD

Exagen Diagnostics Introduces eXaIBS Test and eXaIBD Test

Cimzia® Receives FDA Nod for Treating Crohn's Disease

Kyorin Pharmaceutical Launches Pentasa Tablets 500

Xian-Janssen Introduces Remicade, Branded infliximab in China

HUMIRA® Obtains EU Approval for Treating Crohn's Disease

Salix and Watson to Launch COLAZAL® Authorized Generic

4.RECENT INDUSTRY ACTIVITY

GlaxoSmithKline Enters into Partnerships with Biotica, Dynavax, and Archemix

Sequenom Buys AttoSense Portfolio and Other Assets from SensiGen

Zeria Pharmaceutical to Take Over Tillotts Pharma

Meridian Bioscience Europe Signs Agreement with BUHLMANN Laboratories

Sosei Group Inks Deal with Biocopea

UCB Receives FDA Approval for Cimzia

Regeneron Pharmaceuticals and Sanofi-aventis Extend Global Collaboration

Celldex Therapeutics Acquires CuraGen

Onyx Pharmaceuticals Acquires Proteolix

Roche Acquires ARIUS Research, Inc.

Nycomed Inks Agreement with Immunomedics for Veltuzumab

Archemix Inks Deal with GlaxoSmithKline

Boehringer to Takeover Actimis

J&J PRD Grants Milestone Payment to Sunesis Pharmaceuticals

The Asian Institute of Gastroenterology Establishes New facility

TPG Capital Acquires Axcan Pharma
Cosmo Pharmaceuticals Collaborates with Santarus
BioLineRx Inks License Agreement with Yissum
Salix Pharmaceuticals Secures FDA Approval for APRISO™
Omeros Inks Agreement with Affitech
GlaxoSmithKline Enters into Strategic Alliance with Regulus Therapeutics
Roche to Take Over Piramed
Evotec Acquires Renovis
Takeda Pharmaceutical Acquires Millennium Pharmaceuticals
GlaxoSmithKline Takes Over Sirtris Pharmaceuticals
Boehringer Ingelheim Inks Agreement with Actimis Pharmaceuticals
GlaxoSmithKline Enters into a Strategic Alliance with Archemix
Pipex Pharmaceuticals Buys Oral dnaJP1
Emergent BioSolutions Acquires AVANIR's Anthrax Monoclonal Antibody Collection
Ferring Inks License Agreement with Conaris
ZymoGenetics and Merck Serono Restructure Their Partnership
Evotec Acquires Renovis
ViroPharma Acquires Lev Pharmaceuticals
TPG Capital Inks Agreement to Acquire Axcan Pharma
Meyer Pharmaceuticals Inks Agreement with AnGes
The School of Pharmacy Enters Into Collaboration with Tillotts Pharma
Sequenom Inks Collaborative Agreement with SensiGen
Evotec Signs Collaborative Agreement with Interprotein
Shire Obtains Approval from FDA for LIALDA™ (mesalamine)
Amgen Acquires Avidia
Pipex Pharmaceuticals Acquires Remaining Stake in Effective Pharmaceuticals

5.FOCUS ON SELECT GLOBAL PLAYERS

Abbott Laboratories (US)
Biogen Idec, Inc. (US)
Cosmo Pharmaceuticals SpA (Italy)
ChemoCentryx, Inc. (US)
Dr. Falk Pharma GmbH (Germany)
Eisai Co., Ltd. (Japan)
Elan Corporation, plc (Ireland)
Ferring Pharmaceuticals A/S (Denmark)
GlaxoSmithKline plc (UK)
Johnson & Johnson (US)

Centocor Ortho Biotech, Inc. (US)
Kyorin Pharmaceutical Co., Ltd. (Japan)
Merck Serono (Switzerland)
Millennium Pharmaceuticals, Inc. (US)
Mitsubishi Tanabe Pharma Corporation (Japan)
Novartis AG (Switzerland)
Otsuka Pharmaceutical Co. Ltd. (Japan)
Prometheus Laboratories, Inc. (US)
Shire Plc (UK)
UCB SA (Belgium)
Wyeth (US)

III. COMPETITIVE LANDSCAPE

Total Companies Profiled: 69 (including Divisions/Subsidiaries - 77)

Region/Country/Players

The United States

Canada

Japan

Europe

France

Germany

The United Kingdom

Italy

Spain

Rest of Europe

Asia-Pacific (Excluding Japan)

Middle East

I would like to order

Product name: Inflammatory Bowel Disease Therapeutics: Market Research Report

Product link: <https://marketpublishers.com/r/l67534ADEA7EN.html>

Price: US\$ 3,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/l67534ADEA7EN.html>